Inidascamine

CAS 903884-71-9

MF C12H17N3O2 MW235.28 g/mol

(-)-(2R,3S)-2-amino-3-hydroxy-3-(pyridin-4-yl)-1-(pyrrolidin-1-yl)propan-1-one

(2R,3S)-2-amino-3-hydroxy-3-pyridin-4-yl-1-pyrrolidin-1-ylpropan-1-one

(2R,3S)-2-amino-3-hydroxy-3-(pyridin-4-yl)-1-(pyrrolidin-1-yl)propan-1-one
schizophrenia, 3LW01V88B7, RL 007

Inidascamine (developmental code name RL-007 or FSV7-007) is an experimental, orally administered drug primarily studied for treating Cognitive Impairment Associated with Schizophrenia (CIAS). Developed jointly by Recognify Life Sciences and atai Life Sciences, the molecule targets the underlying neural mechanisms that restrict verbal learning, memory retention, and mental processing speed in schizophrenia patients

Mechanism of Action

The compound is designed to alter the brain’s complex excitatory and inhibitory balance to produce pro-cognitive effects. It accomplishes this by interacting with three major neurotransmitter systems simultaneously:

• Cholinergic system: Modulates acetylcholine pathways vital for attention and memory.
• Glutamatergic system: Interacts with NMDA/glutamate receptors to influence synaptic plasticity.
• GABAergic system: Targets \(GABA_{B}\) receptors to stabilize neural transmission.

Clinical Status & Current Data

• Phase 2b Trial Results: In July 2025, data from a Phase 2b clinical trial showed that while inidascamine produced numerical improvements in memory and processing speed compared to a placebo, it failed to achieve statistical significance on its primary efficacy endpoint.
• Safety Profile: The drug demonstrated excellent tolerability. It lacked common antipsychotic side effects like heavy sedation, rapid weight gain, or involuntary body movements.
• Commercial Backing: Following the trial shortfall, atai Life Sciences officially deprioritized the asset to shift its primary funding toward its wholly owned pipeline of psychedelic therapies.

Inidascamine (INNTooltip International Nonproprietary Name; developmental code names RL-007, FSV7-007) is an experimental drug which is under development for the treatment of cognitive impairment associated with schizophrenia (CIAS).^{[1][3][4][5][6][2]} It is taken orally.^[1][2] The drug is said to act on the cholinergic, NMDA, and GABA_B receptor systems.^[1][5][2] Inidascamine is being developed by Recognify Life Sciences and atai Life Sciences.^[1][3] It was discovered via screening of compounds for effects on synaptic plasticity and cognition.^[2] The drug shows structural similarities to phenethylamines and amphetamines.^[7]

• A Study to Evaluate RL-007 in the Treatment of Cognitive Impairment Associated With Schizophrenia (CIAS)CTID: NCT05686239Phase: Phase 2Status: CompletedDate: 2025-07-30
• Safety, Biomarker Study of RL-007 in Subjects With SchizophreniaCTID: NCT04822883Phase: Phase 2Status: CompletedDate: 2022-04-27

PAT

https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2006081273&_cid=P11-MQ616P-01336-1

OL-threo-2- Amino-3-hvdroxy-3 -(pyridin-4-yl)- 1 -(pyrrolidin- 1 -yDpropan- 1 -one dihydrochloride Compound 22.
Compound 22 was prepared following method E with trans-(4,5-άihydτo-5-(pyridin-4-yl)oxazol-4-yl)(pyrrolidin-l-yl)methanone Compound 19 (0.750 g, 3.07 mmol), hydrochloric acid 37 % (1.0 mL) and methanol (10 mL). After 3.0 h at 50 °C and work-up DL-tAreø-2-amino-3-hydroxy-3-(pyridin-4-yl)-l-(pyrrolidin-l-yl)propan-l-one dihydrochloride Compound 22 was obtained as a white solid (0.935 g, 99 % yield).

Compound 22
MW: 308.28; Yield: 99 %; White Solid; Mp (°C): 117.0.
¹H-NMR (CD₃OD₃ δ): 1.75-2.03 (m, 4H, 2xCH₂), 2.93-3.08 (m, 1H, CHN), 3.32-3.75 (m, 3H, 2xCH₂), 4.54 (d, 1H, J= 5.9 Hz, CH₁N), 5.40 (d, 1H, J = 5.9 Hz, CH-O), 8.21 (d, 2H, J= 5.8 Hz, ArH), 8.94 (d, 2H, J= 5.8 Hz, ArH).
MS-ESI m/z (% rel. int.): 236.1 ([MH]+, 17), 219 (25), 148 (100).
HPLC: Method A, detection UV 254 nm, Compound 22 RT = 0.8 min, peak area 96.3 %.

PAT

• 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds having analgesic and / or immunostimulatory activityPublication Number: ES-2565236-T3Priority Date: 2005-01-26Grant Date: 2016-04-01
• 3-ARYL-3-HYDROXY-2-AMINO-PROPIONIC ACID, 3-HETEROARYL-3-HYDROXY-2-AMINOPROPIONIC ACID AMIDES AND RELATED COMPOUNDS HAVING ANALGESIC AND/OR IMMUNOSTIMULATING ACTIVITYPublication Number: BR-122018068138-B1Priority Date: 2005-01-26
• 1-aryl-1-hydroxy-2,3-diamino-propyl amines, 1-heteroaryl-1-hydroxy-2,3-diamino-propyl amines and related compounds having analgesic and/or immuno stimulant activityPublication Number: US-2011288094-A1Priority Date: 2005-01-26
• 1-aryl-1-hydroxy-2,3-diamino-propyl amines, 1-heteroaryl-1-hydroxy-2,3-diamino-propyl amines and related compounds having analgesic and/or immuno stimulant activityPublication Number: US-9828349-B2Priority Date: 2005-01-26Grant Date: 2017-11-28
• Compounds having analgesic and/or immunostimulant activityPublication Number: US-2012157497-A1Priority Date: 2005-01-26
• 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds having analgesic and/or immunostimulant activityPublication Number: AU-2012241156-A1Priority Date: 2005-01-26
• 3-Aryl-3-hydroxy-2-amino-propionic acid amide, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amide and related compounds having analgesic activity and / or immunostimulatory activityPublication Number: JP-2012162547-APriority Date: 2005-01-26

ADVERTISEMENT

ANAX LABORATORIES

WEBSITE https://www.anaxlab.com/

Discovery Solutions, Supporting the chemistry needs of clients in the Medical, Analytical and Bio Sciences

Development Solutions, Developing from Lab scale to PR&D, Kilo Scale-ups and Commercial Scales

SEE MORE………Integrated Solutions, Manufacturing Solutions, Products,
Can’t Find? Let’s Connect

Phone : +91 897704 2010 /  +91 9177075735, Email : info@anaxlab.com

#MedicinalChemistry, #DrugDiscovery, #OrganicSynthesis, #ChemicalLibrary, #BuildingBlocks, #SARStudies, #ChemistryInnovation, #medchem, #Drugdevelopment, #Biotech, #Biotechnology, #AnaxLaboratories, #Pharma

AS ON FEB2026 4.574 LAKHS VIEWS ON BLOG WORLDREACH AVAILABLEFOR YOUR ADVERTISEMENT

join me on Linkedin

Anthony Melvin Crasto Ph.D – India | LinkedIn

join me on Researchgate

RESEARCHGATE

join me on Facebook

Anthony Melvin Crasto Dr. | Facebook

• Twitter
• FACEBOOK

join me on twitter

Anthony Melvin Crasto Dr. | twitter

+919321316780 call whatsaapp

EMAIL. amcrasto@gmail.com

Clinical data
Other names	RL-007; RL007; FSV7-007
Routes of administration	Oral[1][2]
Identifiers
IUPAC name
CAS Number	903884-71-9
PubChem CID	11535990
ChemSpider	9710771
UNII	3LW01V88B7
ChEMBL	ChEMBL5095258
CompTox Dashboard (EPA)	DTXSID90238113
Chemical and physical data
Formula	C12H17N3O2
Molar mass	235.287 g·mol−1
3D model (JSmol)	Interactive image
SMILES
InChI

References

1.  “RL 007”. AdisInsight. 10 June 2024. Retrieved 26 February 2025.
2.  Donello JE, Walker GA, Schweighoffer F, and Pando MP. Abstract Number: 149. RL-007, a novel oral neuromodulator, enhances synaptic plasticity and cognition in non-clinical models. American College of Neuropsychopharmacology (ACNP) annual meeting. December 5, 2023. https://ir.atai.life/static-files/06c60339-e93c-42fc-9323-c0e38e83f86e
3.  “Delving into the Latest Updates on RL-007 with Synapse”. Synapse. 23 January 2025. Retrieved 26 February 2025.
4.  Brady LS, Lisanby SH, Gordon JA (2023). “New directions in psychiatric drug development: promising therapeutics in the pipeline”. Expert Opinion on Drug Discovery. 18 (8): 835–850. doi:10.1080/17460441.2023.2224555. PMID 37352473.
5.  Vita A, Barlati S, Cavallaro R, Mucci A, Riva MA, Rocca P, et al. (2024). “Definition, assessment and treatment of cognitive impairment associated with schizophrenia: expert opinion and practical recommendations”. Frontiers in Psychiatry. 15 1451832. doi:10.3389/fpsyt.2024.1451832. PMC 11450451. PMID 39371908.
6.  Ye N, Wang Q, Li Y, Zhen X (March 2025). “Current emerging therapeutic targets and clinical investigational agents for schizophrenia: Challenges and opportunities”. Medicinal Research Reviews. 45 (2): 755–787. doi:10.1002/med.22086. PMID 39300769.
7.  “2-Amino-3-hydroxy-3-(pyridin-4-yl)-1-(pyrrolidin-1-yl)propan-1-one, (2R,3S)-“. PubChem. Retrieved 26 February 2025.

//////////inidascamine, ANAX LABS, schizophrenia, 3LW01V88B7, RL 007